Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

Also called NCT02923193

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 306 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02923193
Other papers using this trial's data
  • Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial JACC. Cardiovascular interventions, 2021-06-28 DOI, PubMed 34167675

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Germany, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02923193. Randomized; single masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2020-05-12 (actual). Results posted on 2023-12-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
Condition
Peripheral Arterial Disease
Intervention (Device)
Shockwave Lithoplasty® Peripheral Lithoplasty System
Intervention (Drug)
Medtronic IN.PACT (DCB)
Lead sponsor
Shockwave Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02923193
Content hash
ff7b68f35df3db2fa7f9120f317fe202ee96c228512603f4733446302d80a4ef